ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
233,782
179,804
130,956
24,951
2,782
Cost of Revenue
2,745
2,519
1,371
0
0
Gross Profit
231,037
177,285
129,585
24,951
2,782
Operating Expenses
Research Development
241,436
207,301
191,499
153,893
128,193
Selling General and Administrative
294,709
255,474
273,698
273,596
103,745
Total Operating Expenses
536,145
462,775
465,197
427,489
231,938
Operating Income or Loss
-305,108
-285,490
-335,612
-402,538
-229,156
Interest Expense
37,272
30,523
29,271
14,196
0
Total Other Income/Expenses Net
7,852
6,771
4,516
3,904
2,727
Income Before Tax
-334,528
-309,242
-360,367
-412,830
-226,429
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-334,528
-309,242
-360,367
-412,830
-226,429
Net Income
-334,528
-309,242
-360,367
-412,830
-226,429
Net Income available to common shareholders
-334,528
-309,242
-360,367
-412,830
-226,429
Reported EPS
Basic
-
-10.86
-14.38
-16.74
-9.56
Diluted
-
-10.86
-14.38
-16.74
-9.56
Weighted average shares outstanding
Basic
-
28,464
25,054
24,663
23,694
Diluted
-
28,464
25,054
24,663
23,694
EBITDA
-
-278,719
-331,096
-398,634
-226,429